10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
85.71
+1.60 (1.90%)
At close: Sep 25, 2026, 4:00 PM EDT
85.50
-0.21 (-0.25%)
After-hours: Sep 25, 2026, 7:59 PM EDT
10x Genomics Revenue
10x Genomics had revenue of $151.04M in the quarter ending June 30, 2026, a decrease of -12.65%. This brings the company's revenue in the last twelve months to $616.91M, down -4.28% year-over-year. In the year 2025, 10x Genomics had annual revenue of $642.82M with 5.25% growth.
Revenue (ttm)
$616.91M
Revenue Growth
-4.28%
P/S Ratio
18.10
Revenue / Employee
$523,694
Employees
1,178
Market Cap
11.17B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 642.82M | 32.04M | 5.25% |
| Dec 31, 2024 | 610.79M | -7.94M | -1.28% |
| Dec 31, 2023 | 618.73M | 102.32M | 19.81% |
| Dec 31, 2022 | 516.41M | 25.92M | 5.28% |
| Dec 31, 2021 | 490.49M | 191.65M | 64.13% |
| Dec 31, 2020 | 298.85M | 52.95M | 21.53% |
| Dec 31, 2019 | 245.89M | 99.58M | 68.06% |
| Dec 31, 2018 | 146.31M | 75.23M | 105.83% |
| Dec 31, 2017 | 71.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Koninklijke Philips | 20.18B |
| Zimmer Biomet Holdings | 8.51B |
| Smith & Nephew | 6.30B |
| STERIS | 6.04B |
| Bruker | 3.50B |
| Globus Medical | 3.14B |
| Insulet | 3.05B |
| Bio-Rad Laboratories | 2.59B |
TXG News
- 2 days ago - 10x Genomics rises 7.6% - TheFly
- 16 days ago - 10x Genomics partners with Korea-based Lunit for AI-enabled pathology analysis - TheFly
- 16 days ago - Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research - PRNewsWire
- 17 days ago - 10x Genomics assumed with a Neutral at UBS - TheFly
- 25 days ago - 10x Genomics initiated with a Sector Perform at RBC Capital - TheFly
- 4 weeks ago - 10x Genomics reports patent infringement win against Parse Biosciences - TheFly
- 4 weeks ago - 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences - PRNewsWire
- 5 weeks ago - 10x Genomics price target raised to $65 from $50 at Stephens - TheFly